The patent refers to how ATL1102 inter reacts with some...

The patent refers to how ATL1102 inter reacts with some proteins, and its mode of operation. it is this interaction with some proteins that gives benefit. And these proteins are common in many inflammation disease. So individual disease does need to be mentioned. Just how the drug works and against what. Any disease with this biomarker becomes a target. The patent I have bolded is the one. Spelling went amiss during the copy and paste.

I remember this announcement very well. It was a huge event as this not only gives confidence in how the drug works against DMD, but also is proof that will help the FDA understand that our drug does work. This is something a recent DMD drug couldn't do, but it still got approved.
This also means data gained in one indication adds to data for other indications with the same biomarkers.